Isolation of integral membrane proteins of Leishmania promastigotes and evaluation of their prophylactic potential in hamsters against experimental visceral leishmaniasis

Vaccine

Volumn 23, Issue 9, 2005, Pages 1189-1196

  Garg, Ravendra ^a   Srivastava, J K ^a   Pal, A ^b   Naik, S ^c   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b NeoPharm Inc 1850 Lakeside Dr W   (United Kingdom)

^c SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antibody response; Hamster; Integral membrane protein; Leishmania donovani; LTT; Phase separation; Triton X 114; Vaccination

Indexed keywords

FREUND ADJUVANT; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; PARASITE ANTIGEN; TRITON X 114;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; BONE MARROW; CENTRIFUGATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HAMSTER; HYDROPHILICITY; IMMUNIZATION; LEISHMANIA DONOVANI; LEISHMANIA TROPICA; LIVER; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PARASITE VIRULENCE; PHASE PARTITIONING; PHASE SEPARATION; PRIORITY JOURNAL; PROMASTIGOTE; PROPHYLAXIS; PROTEIN ISOLATION; QUANTITATIVE ANALYSIS; SOLUBILIZATION; SPLEEN; TEMPERATURE; VISCERAL LEISHMANIASIS;

ANIMALS; CRICETINAE; LEISHMANIA; LEISHMANIASIS; MALE; MEMBRANE PROTEINS; PROTOZOAN PROTEINS; PROTOZOAN VACCINES;

EID: 11144231511     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.06.054     Document Type: Article

References (57)

1. WHO. Antimonials: large scale failure in leishmaniasis is alarming. TDR News 1990;34:1-7.
2. WHO. Advances in battle against leishmaniasis. TDR News 1998; 34:1-7.
3. S. Sundar Drug resistance in Indian visceral leishmaniasis Trop Med Int Health 6 11 2001 849 854
4. S. Sundar, D.K. More, M.K. Singh, V.P. Singh, S. Sharma, and A. Makharia Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of Indian epidemic Clin Infect Dis 31 4 2000 1104 1107
5. E. Handman Leishmania vaccines: old and new Parasitol Today 13 1997 236 238
6. J. Convit, P.L. Castellano, A. Rondon, M.E. Penardi, M. Ulrich, and M. Castes Immunotherapy versus chemotherapy in localized cutaneous leishmaniasis Lancet 1 8530 1987 401 414
7. W. Mayrink, P.A. Magalhães, M.S.M. Michalick, C.A. Costa, A.O. Lima, and M.N. Melo Immunotherapy as treatment of American cutaneous leishmaniasis: preliminary studies in Brazil Parasitologia 34 1-3 1992 159 165
8. E.A.G. Khalil, A.M. El Hassan, E.E. Zijlstra, M.M. Mukhtar, H.W. Ghalib, and B. Musa Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double blind. BCG-controlled trial in Sudan Lancet 356 9241 2000 1565 1569
9. S. Gurunathan, D.L. Sacks, D.R. Brown, S.L. Reiner, H. Charest, and N. Glaichenhaus Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania donovani J Exp Med 186 7 1997 1137 1147
10. A. Jardim, D.L. Tolson, S.J. Turco, T.W. Pearson, and R.W. Olafson The Leishmania donovani lipophosphogrycan T lymphocyte reactive component is a tightly associated protein complex J Immunol 147 10 1991 3538 3544
11. Y.A. Skeiky, M. Kennedy, D. Kaufman, M.M. Borges, J.A. Guderian, and J.K. Scholler LeIF: a recombinant Leishmania protein that induces IL-12-mediated TH1 cytokine proffle J Immunol 161 11 1998 6171 6179
12. C.L. Jaffe, N. Rachamim, and R. Sarfstein Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis J Immunol 144 2 1990 699 706
13. I. Muller, V. Fruth, and J.A. Louis Immunology of experimental leishmaniasis Med Microbiol Immunol 181 1 1992 1 12
14. V.O. Da Silva, G.P. Borja-Cabrera, N.N. Correia Pontes, E. Paraguai de Souza, K.G. Luz, and M. Palatnik A Phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante RN) Vaccine 19 9-10 2001 1068 1081
15. G.P. Borja-Cabrera, N.N. Correia Pontes, V.O. da Silva, E. Paraguai de Souza, W.R. Santos, and E.M. Gomes Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante, RN) Vaccine 20 27-28 2002 3277 3284
16. C.B. Palatnik de Sousa, M.B. Moreno, E. Paraguai de Souza, and R. Borojevic The FML vaccine (fucose-mannose ligand) protects hamsters from experimental Kala-Azar Ciencia e Cultura (J Braz Assoc Adv Sci) 46 1994 290 296
17. W.R. Santos, E. Paraguai de Souza, M. Palatnik, and C.B. Palatnik de Sousa Vaccination with the FML antigen (fucose mannose ligand) of Leishmania donovani in the Swiss Albino model Vaccine 17 1999 2554 2561
18. G.P. Borja-Cabrera, A.C. Mendes, E. Paraguai de Souza, L.Y.H. Okadab, F.A. Trivellato, and J.K.A. Kawasaki Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine Vaccine 22 2004 2234 2243
19. W.R. Santos, V.M.F. de Lima, E. Paraguai de Souza, R.R. Bernardo, M. Palatnik, and C.B. Palatnik de Sousa Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis Vaccine 21 2002 30 43
20. D.M. Dwyer Isolation and partial characterisation of surface membranes from Leishmania donovani promastigotes J Protozool 27 2 1980 176 182
21. D. McMahon-Pratt, G. Rodriguez, J.R. Rodriguez, Y.A. Zhang, K. Manson, and C. Bergman Recombinant vaccinia viruses expressing gp46/M-2 protects against leishmania infection Infect Immun 61 8 1993 3351 3359
22. N.D. Connell, H. Medina-Acosta, W.R. Mcmaster, B.R. Bloom, and D.G. Russel Effective immunization against cutaneous leishmaniasis with recombinant Bacillus Calmette-Guerin expressing the Leishmania surface proteinase gp63 Proc Nat Acad Sci USA 90 24 1993 11473 11477
23. M.M. Gicheru, and J.O. Olobo Evaluation of recombinant gp63, the major Leishmania surface glycoprotein as a diagnostic molecule of leishmaniasis in vervet monkeys Acta Trop 58 3-4 1994 345 348
24. J. Champsi, and D. Me Mahon Pratt Membrane glyeoprotein M-2 protects against Leishmania amazonensis infection Infect Immun 56 1988 3272 3279
25. E. Handman, and G.F. Mitchell Immunization with leishmania receptor for macrophages protects mice against cutaneous leishmaniasis Proc Natl Acad Sci USA 82 1986 5910 5914
26. M.J. Mc Conville, A. Bacic, G.F. Mitchell, and E. Handman Lipophosphoglycon of Leishmania major that vaccinate against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor Proc Natl Acad Sci USA 84 1987 8941 8945
27. C. Bordier Phase separation of integral membrane proteins in Triton X-114 solution J Biol Chem 256 1981 1604 1607
28. P.C. Melby, V.V. Tryon, B. Chandrasekar, and G.L. Freeman Cloning of syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis Infect Immun 66 1998 2135 2142
29. S. Mukhopadhyay, P. Sen, S. Bhattacharya, S. Mazumdar, and S. Roy Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis Vaccine 17 1998 289 296
30. J.C. Ray Cultivation of various Leishmania parasites on solid medium Ind. J. Med. Res. 20 1932 355 357
31. J.A. Smyth, R.L. Coppel, G.V. Brown, R. Ramasamy, D.J. Kemp, and R.F. Anders Identification of two integral membrane proteins of Plasmodium falciparum Proc Natl Acad Sci USA 85 1988 5195 5199
32. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randal Protein measurement with folin-phenol reagent J Biol Chem 193 1951 265 275
33. A. Choudhury, P.Y. Guru, R.P. Saxena, A. Tandon, and K.C. Saxena Enzyme linked immunosorbant assay in diagnosis of kala-azar in Bhadohi (Varanasi) India Trans Roy Soc Trop Med Hyg 84 1990 363 367
34. A. Mishra, A. Dube, B. Srivastava, P. Sharma, J.K. Srivastava, and J.C. Katiyar Successful vaccination against Leishmania donvoani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG Vaccine 19 25-26 2001 3485
35. A. Voller, D.E. Bidwell, and A. Bartlett The enzyme linked immunosorbant assay (ELISA): a guide with abstracts of microplate application 1979 Fileroline Press Guernsey Ci pp. 1-125
36. P.M. Kaye, A.J. Curry, and J.M. Blackwell Differential production of Th-1 and Th-2 derived cytokines does not determine the genetically controlled or vaccine induced rate of cure in murine visceral leishmaniasis J Immunol 146 8 1991 2763 2770
37. L.C. Afonso, T.M. Scharton, L.Q. Vieira, M. Wysocka, G. Trinchieri, and P. Scott The adjuvant effect interleukin-12 in a vaccine against Leishmania major Science 263 5144 1994 235 237
38. L.P. Kahl, C.A. Scott, R. Lelchguk, G. Gregoriadis, and R.Y. Liew Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen liposomes. Optimization and assessment of the requirement for intravenous immunizaiton J Immunol 142 12 1989 4441 4449
39. J. Champsi, and D. Mc Mohan Pratt Membrane glycoprotein M-2 protects against Leishmania amazonensis infection Infect Immun 56 12 1988 3272 3279
40. S. Heath, M.L. Chance, M. Hommel, and J.M. Crompton Cloning of a gene encoding the immunodominant surface antigen of Leishmania donovani promastigotes Mol Biochem Parasitol 23 3 1987 211 222
41. C.L. Jaffe, N. Rachamin, and R. Sarfestein Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis J Immunol 144 2 1990 699 706
42. A.C. White Jr., and D. McMahon-Pratt Prophylactic immunization against experimental Leishmania donovani infection by use of a purified protein vaccine J Infect Dis 161 6 1990 1313 1314
43. P.J. Murray, T.W. Spithill, and E. Handman Characterisation of integral membrane proteins of Leishmania major by Triton X-114. Production and analysis of vaccination effect in mice Infect. Immun 57 7 1989 2203 2209
44. M.V. Rogers, K.M. Davern, J. Smythe, and G.F. Mitchell Immunoblotting analysis of the major integral membrane protein antigens of Schistosoma japonicum Mol Biochem Parasitol 29 1 1988 77 87
45. A.E. Balber, and L.M. Ho Trypanosoma brucei gambiense: pantidioning of glyco peptides of blood stream and procyclic forms in Triton X-114 Exp Parasitol 65 2 1988 290 293
46. C. Tanford, and J.A. Reynolds Characterisation of membrane proteins in detergent solutions Biochim Biophys Acta 457 2 1976 133 170
47. S. Mukhopadhyay, S. Bhattacharyya, R.M. Tripti De, K. Naskar, S. Majumdar, and S. Roy Use of an attenuated leishmanial parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis Clin Diagnos Lab Immunol 7 2000 233 240
48. F. Afrin, and N. Ali Adjuvanticity and protective immunity elicited by Leishmania donovani antigens incapsulated in positively charge liposomes Infect Immun 65 6 1997 2371 2377
49. E. Handman Leishmaniasis: current status of vaccine development Clin Microbiol Rev 14 2001 229 243
50. T.W. Holbrook, J.A. Cook, and B.W. Parker Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes Am J Trop Med Hyg 30 4 1981 762 768
51. J.P. Haldar, S. Ghose, K.C. Saha, and A.C. Ghose Cell mediated immune response in Indian kala-azar and post kala-azar dermal leishmaniasis Infect Immun 42 2 1983 702 707
52. S.K. Basak, B. Saha, A. Bhattacharya, and S. Roy Immunobiological studies on experimental visceral leishmaniasis. II. Adherent cell mediated down regulation of delayed type hypersensitivity response and up-regulation of B-cell activation Eur J Immunol 22 8 1992 2041 2045
53. P. Scott, P. Caspar, and A. Sher Protection against leishmania major in Balb/c mice by adoptive transfer of a T-cell clone recognizing a low molecular weight antigen released by promastigotes J Immunol 144 3 1990 1075 1079
54. D.G. Russel, and J. Alexander Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes J Immunol 140 4 1988 1274 1279
55. R.G. Titus, C. Lima, H.D. Engers, and J.A. Louis Exacerbation of cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T-cell populations capable of mediating Leishmania major specific delayed type hypersensitivity J Immunol 133 3 1984 1594 1600
56. A.C. Ghose, J.P. Haldar, S.C. Pal, B.R. Mishra, and K.K. Mishra Serological investigations on Indian Kala-azar Clin Exp Immunol 40 2 1980 318 326
57. R.D. Pearson, and A. De Queiroz Sousa A clinical spectrum of leishmaniasis Clin Infect Dis 22 1 1996 1 13